CVI Holdings’s Evogene EVGN Stock Holding History

CVI Holdings’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-26,164	Closed	-$153K	–	195
2023 Q3	$153K	Buy	+26,164	New	+$229K	0.3%	36

Other funds holding EVGN

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CVI Holdings's EVGN Position: Q4 2023 in Review

CVI Holdings sold out of Evogene (EVGN) in Q4 2023, closing a stake of 26,164 shares — an estimated $153K sold.

CVI Holdings first reported a position in EVGN in Q3 2023 and held it in 1 quarter. The position peaked at $153K in Q3 2023. 33 funds tracked by Wall St. Rank hold EVGN as of Q4 2023.

CVI Holdings reported no remaining Evogene position as of Q4 2023 after selling out during the quarter.
CVI Holdings sold 26,164 Evogene shares in Q4 2023, an estimated $153K.
CVI Holdings first reported a position in Evogene in Q3 2023 and held it in 1 quarter.
CVI Holdings's Evogene position peaked at $153K in Q3 2023.
33 funds tracked by Wall St. Rank held Evogene as of Q4 2023.

Based on CVI Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.